Nothing Special   »   [go: up one dir, main page]

CY1122634T1 - Μεθοδοι και συνθεσεις για thn παρασκευη αερολυματων - Google Patents

Μεθοδοι και συνθεσεις για thn παρασκευη αερολυματων

Info

Publication number
CY1122634T1
CY1122634T1 CY20191100668T CY191100668T CY1122634T1 CY 1122634 T1 CY1122634 T1 CY 1122634T1 CY 20191100668 T CY20191100668 T CY 20191100668T CY 191100668 T CY191100668 T CY 191100668T CY 1122634 T1 CY1122634 T1 CY 1122634T1
Authority
CY
Cyprus
Prior art keywords
methods
compositions
preparation
aerosols
thn
Prior art date
Application number
CY20191100668T
Other languages
English (en)
Inventor
Erik Depla
Mauro Sergi
Peter Casteels
Original Assignee
Ablynx N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx N.V. filed Critical Ablynx N.V.
Publication of CY1122634T1 publication Critical patent/CY1122634T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μεθόδους για την παρασκευή αερολύματος. Ειδικότερα, η παρούσα εφεύρεση παρέχει μεθόδους για την παρασκευή αερολύματος μονών μεταβλητών περιοχών ανοσοσφαιρίνης όπου η ποσότητα σχηματισμού συσσωματωμάτων μειώνεται σημαντικά. Η εφεύρεση περαιτέρω παρέχει αερολύματα τα οποία παρασκευάζονται με τις μεθόδους της εφεύρεσης, καθώς επίσης συνθέσεις για χρήση στις μεθόδους της εφεύρεσης. Η εφεύρεση περαιτέρω αναφέρεται σε μεθόδους για τις παρασκευές τέτοιων συνθέσεων, σε περιέκτες, κιτ και συστήματα αποδέσμευσης αερολύματος που αποτελούνται από τέτοιες συνθέσεις και σε χρήσεις αυτών.
CY20191100668T 2010-02-11 2019-06-26 Μεθοδοι και συνθεσεις για thn παρασκευη αερολυματων CY1122634T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30344710P 2010-02-11 2010-02-11
US201061426610P 2010-12-23 2010-12-23
PCT/EP2011/052024 WO2011098552A2 (en) 2010-02-11 2011-02-11 Methods and compositions for the preparation of aerosols

Publications (1)

Publication Number Publication Date
CY1122634T1 true CY1122634T1 (el) 2021-03-12

Family

ID=43899571

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100668T CY1122634T1 (el) 2010-02-11 2019-06-26 Μεθοδοι και συνθεσεις για thn παρασκευη αερολυματων

Country Status (17)

Country Link
US (3) US9713589B2 (el)
EP (2) EP2533761B1 (el)
JP (3) JP5951508B2 (el)
CN (2) CN105380904A (el)
AU (1) AU2011214299B2 (el)
CA (1) CA2787718C (el)
CY (1) CY1122634T1 (el)
DK (1) DK2533761T3 (el)
ES (2) ES2738114T3 (el)
HK (1) HK1222128A1 (el)
HR (1) HRP20191071T1 (el)
HU (1) HUE044292T2 (el)
LT (1) LT2533761T (el)
PL (2) PL3501499T3 (el)
PT (2) PT2533761T (el)
SI (1) SI2533761T1 (el)
WO (1) WO2011098552A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010289417B2 (en) 2009-09-02 2015-08-13 Synedgen, Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
EP2533761B1 (en) 2010-02-11 2019-03-27 Ablynx N.V. Methods and compositions for the preparation of aerosols
EP3366280A1 (en) 2010-03-12 2018-08-29 Berg LLC Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
EP2720680B1 (en) * 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
EP2897587A1 (en) * 2012-09-18 2015-07-29 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
AU2014233055B2 (en) 2013-03-15 2018-08-09 Board Of Regents, The University Of Texas System Inhibition of pulmonary fibrosis with nutlin-3a and peptides
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CN115177588A (zh) * 2014-04-03 2022-10-14 瑞士杰特贝林生物制品有限公司 免疫球蛋白的雾化
CA2960998A1 (en) * 2014-09-11 2016-03-17 Synedgen, Inc. Compositions and methods of use thereof
EP3204041A1 (en) 2014-10-10 2017-08-16 Ablynx N.V. Methods of treating rsv infections
KR102364212B1 (ko) * 2014-10-10 2022-02-17 아블린쓰 엔.브이. 호흡기 질병들의 에어로졸 치료에 사용하기 위한 흡입 디바이스
KR102698051B1 (ko) * 2015-02-27 2024-08-26 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폴리펩타이드 치료제 및 이의 용도
JP2019523213A (ja) 2016-05-02 2019-08-22 アブリンクス エン．ヴェー． Ｒｓｖ感染の処置
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018220234A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Adamts binding immunoglobulins
KR20210084453A (ko) 2018-09-10 2021-07-07 렁 세라퓨틱스, 인크. Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US6205999B1 (en) 1995-04-05 2001-03-27 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US5586550A (en) 1995-08-31 1996-12-24 Fluid Propulsion Technologies, Inc. Apparatus and methods for the delivery of therapeutic liquids to the respiratory system
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6085740A (en) 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
US6014970A (en) 1998-06-11 2000-01-18 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69738166T2 (de) 1996-06-27 2008-06-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
BR0009866A (pt) 1999-04-22 2002-01-08 Unilever Nv Método de inibição de infecção viral, uso de uma proteìna de ligação de antìgeno monovalente, produto alimentìcio, composição farmacêutica ou cosmética, proteìna de ligação de antìgeno monovalente, sequência de nucleotìdeos, vetor de expressão, célula hospedeira, e, métodos de seleção e de indentificação de uma proteìna de ligação de antìgeno
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
WO2001040310A2 (en) 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
EP1233987B1 (en) 1999-11-29 2009-08-19 Bac Ip B.V. Immobilized single domain antigen-binding molecules
EP1134231B1 (en) 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
WO2004041867A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
WO2005018629A1 (en) 2003-08-12 2005-03-03 Yarbrough William M Treatment for acne vulgaris and method of use
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
RU2433139C2 (ru) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
TW200740843A (en) * 2006-01-24 2007-11-01 Domantis Ltd Ligands that bind IL-4 and/or IL-13
US20110059101A9 (en) 2006-03-13 2011-03-10 Ablynx N.V. Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
US20100129354A1 (en) * 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
EP2102241A2 (en) 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
CA2672965C (en) 2006-12-19 2018-02-06 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
US8906680B2 (en) 2006-12-22 2014-12-09 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
MX2009007406A (es) * 2007-01-09 2010-01-25 Wyeth Corp Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
CN101663319A (zh) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
EP2160409A1 (en) 2007-05-24 2010-03-10 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
KR20120125601A (ko) 2007-05-24 2012-11-16 아블린쓰 엔.브이. Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
EP2220120A2 (en) 2007-11-27 2010-08-25 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
TW200938222A (en) 2007-12-13 2009-09-16 Glaxo Group Ltd Compositions for pulmonary delivery
US9193780B2 (en) 2008-06-05 2015-11-24 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US8945567B2 (en) 2009-06-05 2015-02-03 Ablynx N.V. Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
EP2533761B1 (en) 2010-02-11 2019-03-27 Ablynx N.V. Methods and compositions for the preparation of aerosols

Also Published As

Publication number Publication date
US20130019860A1 (en) 2013-01-24
US12083219B2 (en) 2024-09-10
CA2787718A1 (en) 2011-08-18
PL3501499T3 (pl) 2023-01-09
JP5951508B2 (ja) 2016-07-13
HUE044292T2 (hu) 2019-10-28
JP2016193923A (ja) 2016-11-17
EP2533761A2 (en) 2012-12-19
JP6283064B2 (ja) 2018-02-21
HK1222128A1 (zh) 2017-06-23
JP2018083839A (ja) 2018-05-31
JP7019433B2 (ja) 2022-02-15
EP3501499A1 (en) 2019-06-26
DK2533761T3 (da) 2019-06-24
US9713589B2 (en) 2017-07-25
EP2533761B1 (en) 2019-03-27
WO2011098552A3 (en) 2012-03-29
CN105380904A (zh) 2016-03-09
HRP20191071T1 (hr) 2019-09-20
CN102753148A (zh) 2012-10-24
AU2011214299B2 (en) 2014-07-31
AU2011214299A1 (en) 2012-08-02
LT2533761T (lt) 2019-07-10
WO2011098552A2 (en) 2011-08-18
ES2738114T3 (es) 2020-01-20
SI2533761T1 (sl) 2019-08-30
US11007146B2 (en) 2021-05-18
PT2533761T (pt) 2019-06-17
CN102753148B (zh) 2018-01-26
PT3501499T (pt) 2022-11-22
JP2013519654A (ja) 2013-05-30
EP3501499B1 (en) 2022-09-07
PL2533761T3 (pl) 2019-09-30
US20210346287A1 (en) 2021-11-11
ES2931330T3 (es) 2022-12-28
CA2787718C (en) 2018-05-15
US20170333344A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
CY1122634T1 (el) Μεθοδοι και συνθεσεις για thn παρασκευη αερολυματων
CY1121832T1 (el) Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15)
IL275114B (en) Antibody constructs for cdh19 and cd3 binding sites, preparations containing them, methods for their preparation and uses thereof
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1120471T1 (el) Αντισωματα κατα του cd70
EP3786183A3 (en) Antigen binding constructs to cd3
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
CL2016000344A1 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
EA201790293A3 (ru) Антитела, направленные против icos, и их применения
UA112416C2 (uk) Антитіло до fap і способи його застосування
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX337060B (es) Proceso para preparar una composicion de inmunoglobulina.
EP2560684A4 (en) FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
MX2014011818A (es) Anticuerpos biespecificos contra inductor debil de la apoptosis relacionado con el tnf (tweak) humana e il17 humana y usos de los mismos.
CA2872308A1 (en) Novel ha binding agents
EA201590887A1 (ru) Композиция
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg